## STE: STERIS plc (Ireland) - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.84 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($251.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. iSAM Funds UK Ltd Acquires Shares of 8,433 STERIS plc $STE**
- Source: MarketBeat | 20251209T135600 | Somewhat-Bullish | Relevance: 98%
-  iSAM Funds UK Ltd acquired 8,433 shares of STERIS plc, valued at approximately $2.03 million, during the second quarter. STERIS outperformed earnings expectations, reporting an EPS of $2.47 against an estimated $2.38, and announced a quarterly dividend of $0.63 per share. Despite positive financial results, company insiders have been net sellers, divesting 25,203 shares over the last 90 days.

**2. Has STERIS' 30% 2025 Rally Left Much Value on the Table?**
- Source: Yahoo Finance | 20251206T230600 | Neutral | Relevance: 98%
-  STERIS (STE) has seen a significant 30% rally in 2025, driven by its critical role in healthcare. While a Discounted Cash Flow (DCF) analysis suggests the stock is fairly valued, trading at a slight undervaluation of 8.1%, its Price vs. Earnings (PE) ratio of 37.5x indicates it is overvalued compared to the industry average and its estimated Fair Ratio of 27.0x. Investors can use "Narratives" on Simply Wall St to personalize their valuation based on growth drivers, risks, and competitive positions.

**3. WINTON GROUP Ltd Takes Position in STERIS plc $STE**
- Source: MarketBeat | 20251209T141537 | Somewhat-Bullish | Relevance: 98%
-  WINTON GROUP Ltd initiated a new position in STERIS plc (NYSE:STE) during the second quarter, acquiring 13,215 shares valued at approximately $3.18 million. Institutional investors collectively own about 94.69% of the medical equipment provider's stock, while company insiders have recently been net sellers, divesting 25,203 shares worth about $6.62 million. STERIS reported strong quarterly earnings, beating expectations with an EPS of $2.47 and revenue of $1.46 billion, and announced a quarterly dividend of $0.63.

**4. Thematics Asset Management Trims Stock Position in STERIS plc $STE**
- Source: MarketBeat | 20251208T121541 | Somewhat-Bullish | Relevance: 98%
-  Thematics Asset Management reduced its stake in STERIS plc (NYSE:STE) by 24.6% in the second quarter, selling 36,885 shares and now holding 113,249 shares valued at $27.21 million. Despite this trimming, other institutional investors like Orbis Allan Gray and Norges Bank initiated significant new positions, and UBS AM and Invesco Ltd. materially increased their stakes. STERIS reported a strong EPS beat for the last quarter and provided positive FY2026 guidance, alongside announcing a quarterly dividend.

**5. Federated Hermes Inc. Cuts Position in STERIS plc $STE**
- Source: MarketBeat | 20251209T095914 | Neutral | Relevance: 98%
- Federated Hermes Inc. significantly reduced its stake in STERIS plc (NYSE:STE) by 41.8% in the second quarter, now holding 191,195 shares valued at $45.93 million. This comes amidst varied institutional investment activity, with some firms increasing their holdings while others, including company insiders, have sold shares. STERIS plc reported strong Q3 earnings, beating analyst estimates, and has a consensus "Moderate Buy" rating with an average price target of $273.50.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.84 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.7B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.84 |
| Forward P/E | 23.5 |
| Current P/E | 25.6 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.4% to -1.6% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.0%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.60% (CS: 38) | Neutral |
| RSI_14 | 56.0 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $261.41
- **Stop Loss:** $251.63 (3.7% risk)
- **Target:** $271.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $13,331.91
- **Portfolio %:** 13.33%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*